Add Presentation to Slide Tray Presentation:
First-Generation Versus Second-Generation Antipsychotics in Adults: Comparative Effectiveness
Conclusions (2 of 3)
- For treatment of schizophrenia, most head-to-head evaluations compared haloperidol with the second-generation antipsychotics and found no statistically or clinically significant differences.
- Only olanzapine demonstrated a clinically significant advantage over haloperidol in improving negative symptoms, total scores, and the general psychopathology of schizophrenia. The strength of evidence for this conclusion is moderate.
- For mania and mixed episodes of bipolar disorder, limited evidence suggests similar benefits from haloperidol and aripiprazole for mania, depression, and global scores, and olanzapine and risperidone are similar to haloperidol in effect on mania symptoms. The strength of evidence for these conclusions is low.
- Abou-Setta AM, Mousavi SS, Spooner C, et al. First-Generation Versus Second-Generation Antipsychotics in Adults: Comparative Effectiveness. Comparative Effectiveness Review No. 63 (Prepared by the University of Alberta Evidence-based Practice Center under Contract No. 290-2007-10021). Rockville, MD: Agency for Healthcare Research and Quality; August 2012. AHRQ Publication No. 12-EHC054-EF. Available at www.effectivehealthcare.ahrq.gov/antipsychotics-adult.cfm.
Your slide tray is being processed.